Sema4 Stock – AI-Powered Precision Medicine

If you like buying special purpose acquisition companies (SPACs) at $10 a share, you’ll love buying them at $6.67 a share. A Sober Look at SPACs was a study last year by Stanford and NYU that revealed “by the time the median SPAC merges with a target, it holds just $6.67 in cash for each outstanding share.” So that whole “ten dollars a share is what institutional investors paid” thing isn’t so comforting anymore. Still, there are some SPACs that are worth a look, one of those being Sema4 which is planning to merge with a SPAC called CM Life Sciences (CMLF).

About Sema4

Click for company website

Founded in 2017, Connecticut startup Sema4 took in $241 million in disclosed funding from investors with half of that coming from a July 2020 round led by asset management giant BlackRock (BLK). That money is being used to build a vision of

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.